Studies from New York University (NYU) in the Area of Lung Cancer Reported (Glutamine Antagonist Drp-104 Suppresses Tumor Growth and Enhances Response To Checkpoint Blockade In keap1 Mutant Lung Cancer)

MLA

“Studies from New York University (NYU) in the Area of Lung Cancer Reported (Glutamine Antagonist Drp-104 Suppresses Tumor Growth and Enhances Response To Checkpoint Blockade In Keap1 Mutant Lung Cancer).” Obesity, Fitness & Wellness Week, May 2024, p. 1903. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.791845751&authtype=sso&custid=ns315887.

APA

Studies from New York University (NYU) in the Area of Lung Cancer Reported (Glutamine Antagonist Drp-104 Suppresses Tumor Growth and Enhances Response To Checkpoint Blockade In keap1 Mutant Lung Cancer). (2024, May 4). Obesity, Fitness & Wellness Week, 1903.

Chicago

Obesity, Fitness & Wellness Week. 2024. “Studies from New York University (NYU) in the Area of Lung Cancer Reported (Glutamine Antagonist Drp-104 Suppresses Tumor Growth and Enhances Response To Checkpoint Blockade In Keap1 Mutant Lung Cancer),” May 4. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.791845751&authtype=sso&custid=ns315887.